Background: Dopamine (DA) is an important neurotransmitter with a fundamental role in regulatory functions related to the central, peripheral, renal, and hormonal nervous systems. Dopaminergic neurotransmission dysfunctions are commonly associated with several diseases; thus, in situ quantification of DA is a major challenge. To achieve this goal, enzyme-based biosensors have been employed for substrate recognition in the past. However, owing to their sensitivity to changes in temperature and pH levels. Results: New peptide bioreceptors have been developed. Based on this, 45 in silico bioreceptors were designed to exhibit a higher affinity than that of the DA transporters (DATs). The design was based on the active sites of crystallized enzyme structures that are physiologically related to DA. These affinities were calculated using AutoDock Vina and by assessing the interaction energy between DA and the active DAT site. The controlled variables in the design were amino acids, bond type, steric volume, stereochemistry, affinity, and interaction distances. Conclusions: Three bioreceptor candidates presenting promising values in terms of DA affinity and distance were obtained.
Dopamine (DA) is an important neurotransmitter with a fundamental role in regulatory functions related to the central, peripheral, renal, and hormonal nervous systems. Dopaminergic neurotransmission dysfunctions are commonly associated with several diseases; thus, in situ quantification of DA is a major challenge. To achieve this goal, enzyme-based biosensors have been employed for substrate recognition in the past. However, due to their sensitivity to changes in temperature and pH levels, new peptide bioreceptors have been developed. Therefore, in this study, four bioreceptors were designed in silico to exhibit a higher affinity for DA than the DA transporters (DATs). The design was based on the hot spots of the active sites of crystallized enzyme structures that are physiologically related to DA. The affinities between the chosen targets and designed bioreceptors were calculated using AutoDock Vina. Additionally, the binding free energy, ∆G, of the dopamine-4xp1 complex was calculated by molecular dynamics (MD). This value presented a direct relationship with the E_refine value obtained from molecular docking based on the ∆G functions obtained from MOE of the promising bioreceptors. The control variables in the design were amino acids, bond type, steric volume, stereochemistry, affinity, and interaction distances. As part of the results, three out of the four bioreceptor candidates presented promising values in terms of DA affinity and distance.
Background: Dopamine (DA) is an important neurotransmitter with a fundamental role in regulatory functions related to the central, peripheral, renal, and hormonal nervous systems. Dopaminergic neurotransmission dysfunctions are commonly associated with several diseases; thus, in situ quantification of DA is a major challenge. To achieve this goal, enzyme-based biosensors have been employed for substrate recognition in the past. However, owing to their sensitivity to changes in temperature and pH levels. Results: New peptide bioreceptors have been developed. Based on this, 45 in silico bioreceptors were designed to exhibit a higher affinity than that of the DA transporters (DATs). The design was based on the active sites of crystallized enzyme structures that are physiologically related to DA. These affinities were calculated using AutoDock Vina and by assessing the interaction energy between DA and the active DAT site. The controlled variables in the design were amino acids, bond type, steric volume, stereochemistry, affinity, and interaction distances. Conclusions: Three bioreceptor candidates presenting promising values in terms of DA affinity and distance were obtained.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.